Skip to main content

In Brief This Week: RainDance, Thermo Fisher Scientific, and Celera

NEW YORK (GenomeWeb News) – RainDance Technologies said this week that it has made the first commercial shipment of its RDT 1000 and Sequence Enrichment Solution. The Lexington, Mass.-based firm said that it had shipped the RDT 1000, consumables kits, and custom PCR prime libraries to the Ontario Institute for cancer Research, which will use the products in its discovery and validation of DNA sequence variants associated with cancers.


Thermo Fisher Scientific announced that the University of Middlesex in Hendon, UK, is using its Verso cDNA Synthesis Kit and Absolute Blue QPCR Master Mix in its cancer biomarker research projects.


Celera presented a poster at this week's American College of Medical Genetics meeting in Tampa, Fla., on its prototype Fragile X screening assay. According to the firm, and collaborators from the University of Utah and ARUP Laboratories, the assay "was found to detect expanded alleles in all pre-mutation and full mutation patients with 100 percent sensitivity in both genders, in addition to identifying all non-expanded alleles in patients with 100 percent specificity."


In Brief This Week is a new Friday column containing news items that our readers may have missed during the week.

Filed under

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.